- Home
- NHS vs MNPR Comparison
NHS vs MNPR Comparison
Compare NHS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- MNPR
- Stock Information
- Founded
- NHS 2003
- MNPR 2014
- Country
- NHS United States
- MNPR United States
- Employees
- NHS N/A
- MNPR N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- MNPR Health Care
- Exchange
- NHS Nasdaq
- MNPR Nasdaq
- Market Cap
- NHS 221.6M
- MNPR 229.2M
- IPO Year
- NHS N/A
- MNPR 2019
- Fundamental
- Price
- NHS $7.41
- MNPR $42.96
- Analyst Decision
- NHS
- MNPR Strong Buy
- Analyst Count
- NHS 0
- MNPR 5
- Target Price
- NHS N/A
- MNPR $59.50
- AVG Volume (30 Days)
- NHS 111.8K
- MNPR 24.1K
- Earning Date
- NHS 01-01-0001
- MNPR 05-08-2025
- Dividend Yield
- NHS 13.44%
- MNPR N/A
- EPS Growth
- NHS N/A
- MNPR N/A
- EPS
- NHS N/A
- MNPR N/A
- Revenue
- NHS N/A
- MNPR N/A
- Revenue This Year
- NHS N/A
- MNPR N/A
- Revenue Next Year
- NHS N/A
- MNPR N/A
- P/E Ratio
- NHS N/A
- MNPR N/A
- Revenue Growth
- NHS N/A
- MNPR N/A
- 52 Week Low
- NHS $6.95
- MNPR $1.72
- 52 Week High
- NHS $9.17
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NHS 48.88
- MNPR 61.68
- Support Level
- NHS $7.30
- MNPR $26.06
- Resistance Level
- NHS $7.45
- MNPR $40.90
- Average True Range (ATR)
- NHS 0.21
- MNPR 4.42
- MACD
- NHS 0.03
- MNPR 1.06
- Stochastic Oscillator
- NHS 75.24
- MNPR 91.91
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.